ETHZilla

ETHZilla EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of ETHZilla (ETHZ) as of Nov 3, 2026 is -0.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -10.46 — a change of -97.29% (higher).

EV/EBIT

-0.28

YoY

-97.29%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of ETHZilla is 2025 -0.28 . EV/EBIT (Enterprise Value to EBIT) of ETHZilla was 2024 -10.46 . It decreases by -97.29% higher compared to the previous year.

The ETHZilla EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-3.17 USD
Jan 1, 2020
-11.71 USD
Jan 1, 2021
-4.23 USD
Jan 1, 2022
-3.70 USD
Jan 1, 2023
-4.91 USD
Jan 1, 2024
-10.46 USD
Jan 1, 2025
-0.28 USD
Jan 1, 2026 (e)
-0.10 USD
The ETHZilla EV/EBIT history
YEAREV/EBITYoY
est-0.10-64.72%
-0.28-97.29%
-10.46+113.09%
-4.91+32.80%
-3.70-12.61%
-4.23-63.89%
-11.71+269.39%
-3.17-97.13%
-110.44-42.60%
-192.40-99.10%
-21,342.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ETHZilla Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides ETHZilla's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates ETHZilla's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots ETHZilla's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if ETHZilla grows earnings faster than its peers.

ETHZilla Stock analysis

What does ETHZilla do? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ETHZilla stock

EV/EBIT (Enterprise Value to EBIT) of ETHZilla is -0.28 in 2025.

EV/EBIT (Enterprise Value to EBIT) of ETHZilla changed from -10.46 to -0.28, representing a -97.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) ETHZilla since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s ETHZilla with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ETHZilla

All Key Metrics — ETHZilla